Peptide Knowledge Base · GH-axis

Tesamorelin: what it is, what the evidence says, and its real status

The GH-axis peptide with the strongest pedigree, FDA-approved origins (Egrifta). Available by request and supervised, though compounded forms aren't the approved product.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Tesamorelin work?

A stabilized GHRH analog that stimulates endogenous growth-hormone release; FDA-approved as Egrifta for a specific indication.

What it does — and what it does not do

What it does: Used for GH-axis and metabolic support under clinician supervision.

What it does not do: Compounded versions are not FDA-approved, and it is not a general weight-loss drug.

How honest is the evidence?

Evidence grade A — Strong human evidence.

randomized human trials behind the approved product (Egrifta)

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Long-term use beyond studied indications is less characterized.

WADA status: Banned (S2).

How it is taken

Clinician-set; subcutaneous.

Who should not take it

Banned in tested sport (WADA S2); contraindicated in active malignancy and pregnancy. Clinician-gated.

Sources

Falutz et al., tesamorelin trials, NEJM 2007 · FDA Egrifta labeling

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.